Tellgen Corp

Tellgen Life Science released its 2026 interim report on August 25, 2026. The company's total operating revenue was 187 million yuan, net profit attributable to the parent company was 11.4765 million yuan, and net cash inflow from operating activities was 104 million yuan. The company's latest asset-liability ratio was 26.73%, an increase of 13.57 percentage points compared with the same period last year. The latest gross margin was 67.04%, the latest return on equity was 0.80%, and diluted earnings per share was 0.07 yuan. The company's latest total asset turnover was 0.09 times, and the latest inventory turnover was 0.67 times. The number of shareholders was 17,100, and the top ten shareholders held 64.7025 million shares, accounting for 39.87% of the total share capital.

Tellgen Life Sciences announced that six medical device registration applications submitted by the company and its controlling subsidiary Maishi Biotech have been accepted by the Shanghai Medical Products Administration. The six applications include four Alzheimer's disease auxiliary diagnostic kits and two mass spectrometry detection kits. The above products are still in the registration application acceptance stage and will not have an impact on recent performance.